Using fractional laser and our proprietary technology, FoLix stimulates hair follicles by activating the body's natural healing processes, delivering results in 4-6 monthly sessions. Unlike most options currently available, it does so without chemicals, needles, surgery, or downtime.
FoLix offers an effective, non-invasive solution with minimal discomfort for patients. Combined with its user-friendly design and strong safety profile, it is a compelling option for practitioners that want to offer real results with low-risk and high patient satisfaction.
MDN: What is your perspective on the importance of rigorous clinical validation in building trust with both providers and patients?
Tzipi Ozer-Armon: At Lumenis, we prioritize robust clinical research and real-world evidence to support every product we bring to the market. FoLix, for instance, is backed by clinical data demonstrating safety and efficacy, and showing improvement in hair count, thickness, and overall scalp appearance for patients suffering from hair loss. Lumenis continues to collaborate with global hair loss experts to generate additional meaningful clinical evidence for the efficacy of the FoLix solution.
We know that rigorous clinical validation builds confidence, both among providers and patients, and ensures that our solutions are not only safe but also deliver measurable, repeatable results across diverse patient populations and clinical settings.
MDN: What makes Lumenis a standout brand over others in the industry?
Tzipi Ozer-Armon: Lumenis distinguishes itself in the aesthetic and eye care domains through our unique blend of innovation, clinical expertise, and deep understanding of the needs of both providers and patients.
As a global leader in medical lasers and light-based technologies for nearly 60 years, our legacy is one of trailblazing energy-based technologies. From pioneering the first Intense Pulsed Light (IPL) treatments to introducing sophisticated muscle stimulation and radio-frequency solutions, we have been at the forefront of shaping the medical aesthetics landscape. With over 330 patented technologies and counting, this commitment to innovation has revolutionized the provider experience, redefined the standards of treatment performance, and consistently raised the bar for patient outcomes.
In a crowded market, Lumenis stands out not only for our technological advancements but also for our unwavering dedication to clinical excellence. With our science-backed approach, well-researched and documented in over 550 clinical publications, professionals worldwide can trust our technologies to deliver safe, impactful results.
MDN: How do you envision the future of energy-based medical devices evolving, and what role will Lumenis play in that future?
Tzipi Ozer-Armon: The future of energy-based medical devices is poised for a remarkable transformation, driven by personalization and the seamless integration of digital technologies. At Lumenis, we envision a landscape where smart, connected solutions not only enhance the efficiency and effectiveness of care delivery but also maximize clinical results and improve patient outcomes and safety.
For instance, real-time, adaptive approaches will allow providers to tailor treatments to individual needs, ensuring a more personalized experience that enhances both efficacy and safety. By streamlining practices through technology, we aim to create an environment where clinicians with varying levels of experience can deliver optimal patient care with confidence.
In this rapidly evolving landscape, we are investing in a robust R&D pipeline that fosters the development of next-generation solutions. Our dedication to improving clinical results and safety drive us to continuously push boundaries, ultimately transforming the way aesthetic treatments are delivered and experienced.
MDN: How is Lumenis leveraging technologies such as digital health and remote connectivity to enhance its product ecosystem and improve patient and customer outcomes?
Tzipi Ozer-Armon: We're embedding connectivity into our systems to enable remote diagnostics, usage analytics, treatment tracking, and real-time device performance monitoring. This connectivity empowers clinicians to monitor device performance, gain real-time business insights, and track patient progress. Our goal is to create a seamless network where technology, data, and human expertise come together to deliver superior patient outcomes and improved operational efficiency.
MDN: How does your company foster a culture of innovation across its teams and product development cycles?
Tzipi Ozer-Armon: Innovation has always been in our DNA, and it's something we actively nurture across every part of our company.
We foster cross-functional collaboration, encourage early adoption of breakthrough technologies like AI, and keep our teams deeply connected to our customers. Our R&D and product teams don't innovate in isolation; they work side-by-side with clinicians, end-users, and partners to ensure every solution addresses real-world needs. Through our global network of KOLs (key opinion leaders), outside experts, and long-standing partnerships with medical and aesthetics professionals, we're not only responding to today's challenges but we're also advancing the frontiers of beauty and wellbeing for the future.
MDN: What's next for FoLix and Lumenis?
Tzipi Ozer-Armon: We're focused on expanding FoLix's global footprint. With its ability to easily fit into a wide range of practice groups' pre-existing offerings, the treatment has already achieved rapid expansion into various international markets, including Canada, Japan, Ukraine, and the Middle East within its first year since launch.
We marked a significant milestone recently with the launch of FoLix into the Australia and New Zealand markets, another step in its international expansion, and we have plans to make it available in additional countries and markets soon.
We are exploring additional technologies to further enhance FoLix's efficacy and ease of use, and are also exploring new treatments and indications where our cutting-edge technology can make a meaningful impact.
"Beyond the Laser: Lumenis CEO on Digital Health, Clinical Rigor, and the Future of Aesthetics" was originally created and published by Medical Device Network, a GlobalData owned brand.